CRISPR Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- CRISPR Therapeutics's estimated annual revenue is currently $92.1M per year.
- CRISPR Therapeutics received $113.8M in venture funding in January 2018.
- CRISPR Therapeutics's estimated revenue per employee is $180,884
- CRISPR Therapeutics's total funding is $127M.
- CRISPR Therapeutics has 509 Employees.
- CRISPR Therapeutics grew their employee count by 0% last year.
What Is CRISPR Therapeutics?
CRISPR Therapeutics is a leading gene-editing company focused on the development of transformative medicines using its proprietary CRISPR/Cas9 gene-editing platform. CRISPR/Cas9 is a revolutionary technology that allows for precise, directed changes to genomic DNA. Our multi-disciplinary team of world-class researchers and drug developers is working to translate this technology into breakthrough human therapeutics in a number of serious diseases. Our lead programs in beta-thalassemia and sickle cell disease have advanced to IND/CTA-enabling studies with a CTA filing planned by the end of 2017, and we are advancing additional programs in ex vivo and in vivo disease areas. In addition to our fully-owned programs, our strategic collaborations with Bayer AG and Vertex Pharmaceuticals expand our portfolio and enable us with unique capabilities. Through our private financings, partnerships, and IPO we have raised >$400M to fund and accelerate our portfolio. We have licensed the foundational CRISPR/Cas9 patent estate for human therapeutic use from our scientific founder, Dr. Emmanuelle Charpentier, who co-invented the application of CRISPR/Cas9 for gene editing. Our company is headquartered in Zug, Switzerland with R&D operations in Cambridge, Massachusetts, USA and some business operations in London, United Kingdom.keywords:N/A
Number of Employees
Employee Growth %
CRISPR Therapeutics News
In the last reported quarter, CRISPR Therapeutics witnessed a negative earnings surprise of 5.8%. CRISPR Therapeutics AG Price and EPS Surprise.
CRISPR Therapeutics AG is currently a Zacks Rank #4 (Sell). The Medical - Biomedical and Genetics industry is part of the Medical sector. This...
CRISPR Therapeutics is a leading gene editing company focused on developing transformative gene-based medicines for serious diseases using its...
CRISPR Therapeutics received a grant from the Bill & Melinda Gates Foundation to research in vivo gene editing therapies for the treatment of HIV. The grant builds upon CRISPR Therapeutics’ proprietary CRISPR/Cas9 gene editing technology and expertise in editing hematopoietic stem cells and cont ...
David Liu may be best known as a CRISPR trailblazer behind Editas Medicine, Beam Therapeutics and Prime Medicine. But more than six years ago, he worked with a student from his Harvard lab and then-colleague Alan Saghatelian on a much different project: developing a small mol ...
|Company Name||Revenue||Number of Employees||Employee Growth||Total Funding|
CRISPR Therapeutics Funding
|2018-01-04||$115.0M||Undisclosed||Goldman Sachs & Co. LLC||Article|
|2018-01-08||$113.8M||Undisclosed||Goldman Sachs & Co. LLC||Article|